syntheses

Counter-Intuitive Insights from Ishamma's Medical Data

Counter-Intuitive Insights from Ishamma's Medical Data

1. The "cured" diabetes is probably an illusion

HbA1c dropped dramatically from 6.8% (diabetic) to 5.7% (pre-diabetic) — but this almost certainly doesn't reflect real glycemic improvement. HbA1c measures glycation of hemoglobin over ~120 days. Ishamma's RBC turnover is massively accelerated due to AML + chemotherapy + transfusions, meaning her red cells don't live long enough to accumulate normal glycation. The same disease that's threatening her life is making her diabetes "look" better on paper. If fructosamine or CGM were tested, glucose control might be unchanged. See Diabetes Mellitus, Hba1C, Hemoglobin.

Gap: No fructosamine or glycated albumin has been measured to verify true glycemic status.

2. Her liver is suspiciously healthy

She's on three hepatotoxic drugs simultaneously — Venetoclax, Azacitidine, and Posaconazole — for 4+ months. Her LFTs are not just "okay," they're trending downward (ALT 14→11→11, AST 19→16→15, ALP 77→60→63). In most patients, at least mild transaminase elevation is expected. This degree of hepatic resilience in an 81-year-old is genuinely unusual and raises the question of whether she's a favorable CYP metabolizer — which would also have implications for venetoclax drug levels. See Lft.

Gap: No pharmacogenomic testing to explain the liver resilience.

3. The biggest immediate threat isn't the cancer — it's a fall

Ishamma has adverse-risk AML with a constellation of bad mutations. But the data shows she's actually responding well to Aza-Ven (cellularity 60%→25-30%, Hb 6.8→10.5, ESR 130→40). The more immediate existential risk is the combination of factors creating extreme fall risk: age 81 + Anemia + Hyponatremia (cognitive fog, gait instability) + hypomagnesemia (muscle weakness) + chemo fatigue + no documented home safety assessment. A hip fracture would likely end her treatment and functional independence. See Qol Bang For Buck.

Gap: No home safety assessment documented.

4. The 2022 mystery episode may be more significant than anyone thinks

In September 2022, she had CRP 128 mg/L, ESR 119, WBC 14,770, and IgE 203 — a massive inflammatory storm that nobody ever diagnosed. Three years later, she has AML with MDS-related mutations. MDS-related AML often develops over years from clonal hematopoiesis. That 2022 episode — which also showed elevated platelets (501K, reactive thrombocytosis) and mild anemia (Hb 11.0) — could have been the first clinical signal of the dysplastic clone, presenting as an exaggerated inflammatory response. The 2022 labs look nothing like 2025 (high WBC + high platelets vs. pancytopenia), which itself is interesting — the clone may have shifted from a proliferative to a failure phenotype. See Profile, Esr, Crp.

Gap: The 2022 inflammatory episode has no diagnosis or follow-up documentation.

5. Dropping pegfilgrastim may have been the right wrong decision

Pegfilgrastim was discontinued because of bone pain — a patient comfort decision. But looking at the ANC data: her ANC has actually been manageable without G-CSF support (ANC 2590 on Apr 13, well above the neutropenic threshold). Meanwhile, there's a theoretical concern in the literature that G-CSF in AML can stimulate residual leukemic clones, particularly with her NRAS mutation which activates the same RAS-MAPK pathway that G-CSF signals through. A decision made purely for comfort may have been independently correct for disease biology reasons.

6. Sodium keeps falling even as everything else improves

Most of her labs tell a recovery story: Hb up, WBC normalizing, ESR plummeting, platelets recovering, LFTs pristine. But Sodium has diverged from this trend — it was perfectly normal (136-139) pre-treatment and through January 2026, then developed persistent hyponatremia (129-135) that has not corrected even as the cancer is responding. This suggests the hyponatremia is treatment-driven (likely SIADH from azacitidine) rather than disease-driven — meaning it won't fix itself with continued treatment and needs independent evaluation. The concordant hypochloremia and normal Potassium/Bicarbonate pattern supports a dilutional (SIADH) mechanism.

Gap: Hyponatremia workup (serum osm, urine osm, urine Na) has never been ordered.

7. The positive ANA is probably meaningless — but the workup it triggered was invaluable

ANA 2.2 in an 81-year-old is likely age-related noise (ANA positivity rates approach 25-30% in the elderly). But the autoimmune workup it prompted ended up ruling out several important mimics of pancytopenia: SLE (anti-dsDNA negative, complements normal), RA (anti-CCP negative), myeloma (SPEP clean, free light chains polyclonal), and Wilson's disease (copper + ceruloplasmin normal). A "false positive" generated the most thorough differential diagnosis workup in the record. See Positive Ana.

8. Posaconazole is doing double duty — and saving money

Posaconazole is prescribed for antifungal prophylaxis, but its more important role may be as a deliberate pharmacokinetic hack. As a strong CYP3A4 inhibitor, it forces venetoclax dose reduction from 400mg to 50-100mg — a 75-87% dose reduction that dramatically lowers drug cost. The treating team in India is using a drug interaction that would normally be a safety concern as a cost-optimization strategy. And the LFT data shows the liver is handling this combination without any stress. See Posaconazole, Venetoclax, Lft.

Summary

The most important takeaways are that the diabetes improvement is likely artifactual, the cancer response is paradoxically not the most urgent concern (falls are), and several "incidental" findings (ANA, posaconazole interaction, pegfilgrastim discontinuation) have turned out to be more significant — or less significant — than they initially appeared.

Related Pages

[!note] This is a personal record-keeping analysis, not medical advice. All clinical decisions should be discussed with the treating oncology team.

Filed: 2026-04-19.

Care Insights · wiki page · syntheses/counter-intuitive-insights